about
Renal artery stenosis-when to screen, what to stent?Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicityPrognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population studyEffect of ibuprofen on cardioprotective effect of aspirinIs there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialEffect of diuretics on fetal growth: A drug effect or confounding by indication? Pooled Danish and Scottish cohort dataThe unintended consequences of clinical trials regulations.Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.Oral contraceptives and myocardial infarction: results of the MICA case-control studyAutomated data capture from free-text radiology reports to enhance accuracy of hospital inpatient stroke codes.Promoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign.Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.Effectiveness of newspaper advertising for patient recruitment into a clinical trial.Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.Practice factors that influence antibiotic prescribing in general practice in Tayside.Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the communityGlaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring UnitParacetamol toxicity: epidemiology, prevention and costs to the health-care system.Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population.COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysisAdherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit.Impact of allopurinol use on urate concentration and cardiovascular outcomeDoes offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence.Risk of myocardial infarction in young female smokers.Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs.Application of a propensity score to adjust for channelling bias with NSAIDs.Paracetamol-related deaths in Scotland, 1994-2000.The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension.The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertensionMonotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial
P50
Q26829330-1BAF6C24-4BD2-4544-9844-81C997CE5A29Q28166985-9F25579B-005F-43E1-AEF2-8532D0AF09D2Q28193179-344B1A96-E625-4879-9E24-3CA72E99FB7BQ28195016-EE9AAFB7-CBEB-46DE-AB86-8C6E24FF2C51Q28196511-96210858-33C0-47D9-8F17-46DC2926FADBQ28286410-E7EF3BD5-2920-46C1-86F9-5DA69F19D266Q30640683-681F3E94-0006-416A-873E-C77050C19F4DQ30887196-2F131DE0-588C-4A00-905F-4C2644A071E9Q33284161-F96853FE-3E96-4B62-8142-0A6FA61E566CQ33619425-D58083BD-60F8-43F9-B0C2-869ED50A2E47Q33625233-BE30128C-FD1D-47F2-8258-A792C387BCEEQ33633652-580ADDC5-19FC-4E99-AE98-02333B72A121Q33666086-CB0B283A-8738-4ED4-9904-1FC9C7324F5CQ33888009-85BD1A9F-227C-4811-A2F3-6983647D3FA1Q33936187-C3471CBC-029C-4670-9B81-E22A10EF99D9Q33996337-FB5DEC76-F3D3-44AB-973E-A8723D6DC3AEQ34026831-620EA2CD-5E1F-4C85-B45D-51012FE504D1Q34054974-090D8B96-EDE5-4772-80A7-FAE7202297FEQ34069511-50A92D10-084A-4724-BA34-A94B7254B7C1Q34146971-5E1020AB-064A-4D9A-B24B-F2F7D0AC35FAQ34167806-97573059-DD64-47D7-B29C-6339A67A738BQ34398263-0D456E57-5348-4425-919C-C8BCD68D3CABQ34531806-67687E89-0F66-4E19-80DC-2DA76790897DQ34541234-6790AA92-ABCF-4FFA-A137-97722DC5FB3CQ34542518-4C7E29A8-87A5-4186-87F3-ADD047C45EDCQ34551086-F7516F7E-49ED-4548-8BC7-BB3D812DDD82Q34743735-5F70E247-F853-430C-9420-A2C4A806B398Q34830158-C77D6BCD-797E-4CFA-831F-875549519A09Q35190321-6677BF0C-60C2-427B-AE6D-9A89D2F4C709Q35374439-791568E9-3118-4499-A6A2-6D951C6897D6Q35566701-0887A1D1-E5D1-4BD3-BA51-3AC7FA4F0363Q35595971-1A03BA93-F163-4EE6-94E5-8EAD76E5CF8BQ35770945-75620AE4-EABD-411B-8A5C-D7722E162059Q35788298-995A8C05-3D9E-44FA-AE60-4D05B5BFD6E9Q35804069-C291439D-5CBC-4E81-A5F3-481CB8FCDDE0Q35825838-9F9C04CD-3CD3-4D9C-9B24-B27C97042D5BQ35827206-34B47A0C-C8FA-4ABE-B288-C907C12F6BFDQ35827790-506E85B6-A933-4254-B94E-46F0C8BA3789Q35959952-FDEA0F5C-0A52-48C9-B426-6753585E7502Q35963836-8F961B3A-DA0C-4AB0-A6E6-D2CDF257DDA4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Macdonald
@ast
Thomas Macdonald
@en
Thomas Macdonald
@es
Thomas Macdonald
@nl
Thomas Macdonald
@sl
Томас Макдональд
@ru
type
label
Thomas Macdonald
@ast
Thomas Macdonald
@en
Thomas Macdonald
@es
Thomas Macdonald
@nl
Thomas Macdonald
@sl
Томас Макдональд
@ru
altLabel
Tom
@en
prefLabel
Thomas Macdonald
@ast
Thomas Macdonald
@en
Thomas Macdonald
@es
Thomas Macdonald
@nl
Thomas Macdonald
@sl
Томас Макдональд
@ru
P106
P21
P31
P496
0000-0001-5189-6669